Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Sermorelin
Also known as: Geref, GRF 1-29, Sermorelin Acetate
Sermorelin is a synthetic analog of the first 29 amino acids of naturally occurring GHRH, and it was the first GHRH analog approved by the FDA for diagnostic use and treatment of growth hormone deficiency in children. It stimulates the pituitary to produce and release GH through the natural regulatory pathway. It has an established clinical safety record spanning decades.
Risk Level
Low RiskDifficulty
Beginner| CAS Number | 86168-78-7 |
| Molecular Formula | C149H246N44O42S |
| Class | Peptide |
| Category | Well-Known Peptides |
Mechanism of Action
Sermorelin binds to the GHRH receptor on anterior pituitary somatotrophs, activating the cAMP/PKA signaling cascade that promotes GH gene transcription and pulsatile GH secretion. Because it works through the physiological GHRH pathway, the body's somatostatin feedback mechanism remains intact, preventing excessive GH levels. It also promotes slow-wave sleep, during which natural GH pulses are most robust.
Dosing Research
Clinical doses range from 200-500 mcg subcutaneously once daily at bedtime. In pediatric GH deficiency, doses of 30 mcg/kg/day have been studied. Cycles of 3-6 months are typical, with some protocols recommending continuous use.
Side Effects & Risks
Side effects are generally mild and include injection site pain, redness, and swelling. Facial flushing, headache, and dizziness may occur shortly after injection. Rare reports of difficulty swallowing and allergic reactions exist. Long-term safety data is favorable compared to exogenous GH.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.